Nipro
8086.TPrecision Instruments
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥660.5bn | ¥644.6bn | ¥586.8bn | ¥545.2bn | ¥494.8bn | ¥455.6bn |
| Operating income | ¥37.6bn | ¥26.6bn | ¥22.3bn | ¥17.7bn | ¥23.9bn | ¥27.6bn |
| Ordinary income | ¥19.7bn | ¥10.8bn | ¥19.5bn | ¥15.3bn | ¥27.6bn | ¥26.3bn |
| Net income (owners) | ¥13.5bn | ¥5.1bn | ¥11.1bn | ¥4.6bn | ¥13.5bn | ¥14.2bn |
| Total assets | ¥1.21T | ¥1.17T | ¥1.11T | ¥1.03T | ¥930.3bn | ¥854.4bn |
| Net assets / equity | ¥334.8bn | ¥311.6bn | ¥269.8bn | ¥242.2bn | ¥199.9bn | ¥174.1bn |
| Operating cash flow | ¥54.7bn | ¥68.5bn | ¥72.9bn | ¥10.4bn | ¥68.2bn | ¥66.1bn |
| EPS (basic) | ¥82.8 | ¥31.36 | ¥68.12 | ¥28.05 | ¥82.5 | ¥87.12 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2025-09-30 | Half-year | 74 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 74 figures · EDINET |
24 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Medical Treatment Related | ¥523.6bn | ¥52.3bn |
| Medicine Related | ¥81.1bn | ¥12.1bn |
| Pharma Packaging | ¥54.7bn | −¥1.6bn |
| Other segments | ¥1.1bn | ¥940m |
| Adjustments & eliminations | — | −¥26.2bn |
| Total | ¥659.4bn | ¥62.8bn |
| Total | ¥660.5bn | ¥63.8bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.